These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21521775)

  • 41. Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells.
    Ramasamy K; Khatun H; Macpherson L; Caley MP; Sturge J; Mufti GJ; Schey SA; Calle Y
    Br J Haematol; 2012 Jun; 157(5):564-79. PubMed ID: 22428569
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
    Oneyama C; Ikeda J; Okuzaki D; Suzuki K; Kanou T; Shintani Y; Morii E; Okumura M; Aozasa K; Okada M
    Oncogene; 2011 Aug; 30(32):3489-501. PubMed ID: 21383697
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
    Zheng W; Guan M; Zhu L; Cai Z; Chung V; Huang H; Yen Y
    Anticancer Res; 2010 Jun; 30(6):1921-30. PubMed ID: 20651335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alteration of cell-cell and cell-matrix adhesion in urothelial cells: an oncogenic mechanism for mutant FGFR3.
    di Martino E; Kelly G; Roulson JA; Knowles MA
    Mol Cancer Res; 2015 Jan; 13(1):138-48. PubMed ID: 25223521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with
    Hahn NM; Bivalacqua TJ; Ross AE; Netto GJ; Baras A; Park JC; Chapman C; Masterson TA; Koch MO; Bihrle R; Foster RS; Gardner TA; Cheng L; Jones DR; McElyea K; Sandusky GE; Breen T; Liu Z; Albany C; Moore ML; Loman RL; Reed A; Turner SA; De Abreu FB; Gallagher T; Tsongalis GJ; Plimack ER; Greenberg RE; Geynisman DM
    Clin Cancer Res; 2017 Jun; 23(12):3003-3011. PubMed ID: 27932416
    [No Abstract]   [Full Text] [Related]  

  • 47. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
    Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
    Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
    Cassinelli G; Ronchetti D; Laccabue D; Mattioli M; Cuccuru G; Favini E; Nicolini V; Greco A; Neri A; Zunino F; Lanzi C
    Biochem Pharmacol; 2009 Nov; 78(9):1139-47. PubMed ID: 19555670
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
    Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
    Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
    Leleu X; Jia X; Runnels J; Ngo HT; Moreau AS; Farag M; Spencer JA; Pitsillides CM; Hatjiharissi E; Roccaro A; O'Sullivan G; McMillin DW; Moreno D; Kiziltepe T; Carrasco R; Treon SP; Hideshima T; Anderson KC; Lin CP; Ghobrial IM
    Blood; 2007 Dec; 110(13):4417-26. PubMed ID: 17761832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
    Chen J; Lee BH; Williams IR; Kutok JL; Mitsiades CS; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Moore S; Huntly BJ; Fabbro D; Anderson KC; Griffin JD; Gilliland DG
    Oncogene; 2005 Dec; 24(56):8259-67. PubMed ID: 16091734
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fibroblast growth factor receptor 3 (FGFR3) associated with the CD20 antigen regulates the rituximab-induced proliferation inhibition in B-cell lymphoma cells.
    Kotani N; Ishiura Y; Yamashita R; Ohnishi T; Honke K
    J Biol Chem; 2012 Oct; 287(44):37109-18. PubMed ID: 22932894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
    Castillo JJ; Hunter ZR; Yang G; Treon SP
    Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia.
    Chitta K; Paulus A; Caulfield TR; Akhtar S; Blake MK; Ailawadhi S; Knight J; Heckman MG; Pinkerton A; Chanan-Khan A
    Blood Cancer J; 2014 Nov; 4(11):e260. PubMed ID: 25382610
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In silico prediction and in vitro and in vivo validation of acaricide fluazuron as a potential inhibitor of FGFR3 and a candidate anticancer drug for bladder carcinoma.
    Ke K; Li H; Yao H; Shi XN; Dong C; Zhu Y; Liu X; Li L; Leung KS; Wong MH; Liu XD; Kung HF; Lin MC
    Chem Biol Drug Des; 2017 Apr; 89(4):505-513. PubMed ID: 27664399
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microarray demonstrates different gene expression profiling signatures between Waldenström macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
    Trojani A; Greco A; Tedeschi A; Lodola M; Di Camillo B; Ricci F; Turrini M; Varettoni M; Rattotti S; Morra E
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):208-10. PubMed ID: 23477935
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
    Fulciniti M; Martinez-Lopez J; Senapedis W; Oliva S; Lakshmi Bandi R; Amodio N; Xu Y; Szalat R; Gulla A; Samur MK; Roccaro A; Linares M; Cea M; Baloglu E; Argueta C; Landesman Y; Shacham S; Liu S; Schenone M; Wu SL; Karger B; Prabhala R; Anderson KC; Munshi NC
    Blood; 2017 Apr; 129(16):2233-2245. PubMed ID: 28096095
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A new tubulin polymerization inhibitor, auristatin PE, induces tumor regression in a human Waldenstrom's macroglobulinemia xenograft model.
    Mohammad RM; Limvarapuss C; Wall NR; Hamdy N; Beck FW; Pettit GR; Al-Katib A
    Int J Oncol; 1999 Aug; 15(2):367-72. PubMed ID: 10402249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway.
    He Y; Wu X; Cao Y; Hou Y; Chen H; Wu L; Lu L; Zhu W; Gu Y
    Neoplasma; 2016; 63(4):523-31. PubMed ID: 27268915
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
    Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
    Mol Cancer Ther; 2014 Apr; 13(4):776-87. PubMed ID: 24448819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.